Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19
Article
[키워드] 30-Day mortality
Administered
administration
adverse event
adverse events
analysed
Biomarker
C-reactive protein
clinical
Clinical improvement
cohorts of patient
comparable
complementary
Complementary therapies
coronavirus disease
COVID-19
Critical
Critical care
decrease
Efficacy
epidemiologically
group
hospitalised
Hypothesis
inflammatory parameters
knowledge
lactate dehydrogenase
medication
Mortality
onset of symptom
outcome
Patient
patients with COVID-19
pharmacological treatment
Pneumonia
Primary outcome
pulmonary medicine
Quotient
radiological
radiological improvement
radiology
randomised controlled trial
reductions in
SaO_{2}
secondary
Severe COVID-19 pneumonia
statistically significant difference
subgroup
subgroups
the timing
therapy
Tocilizumab
tocilizumab administration
two group
were recorded
while
[DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기
[DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기